Related Experiment Videos
Histamine and selenium in lung cancer
Filippo Della Rovere1, Angelo Granata, Dario Familiari
1U.O.C. di Chirurgia Toracica, Università degli Studi di Messina, Azienda Ospedaliera Universitaria G. Martino, Messina, Italy. fdellarovere@unime.it
Anticancer Research
|August 5, 2006
Summary
Lung cancer patients show significantly lower plasma levels of histamine and selenium. These findings suggest histamine and selenium may play roles in lung cancer development and could be targets for future therapies.
Area of Science:
- Oncology
- Immunology
- Environmental Health
Background:
- Allergies and cancer incidence are being studied, focusing on histamine's immune roles and tumor inhibition.
- Histamine's influence on free radicals and selenium's known role in lung cancer genesis were investigated.
Purpose of the Study:
- To investigate the relationship between histamine and selenium plasma levels in lung cancer patients.
- To explore the potential roles of histamine and selenium in lung cancer pathogenesis.
Main Methods:
- Assayed plasma histamine and selenium levels in 37 male lung cancer patients and 39 healthy male controls.
- Analyzed the influence of smoking on histamine levels in both groups.
Main Results:
- Lung cancer patients had significantly lower plasma histamine levels (p=0.0038) compared to controls.
- Smoking significantly reduced histamine levels in cancer patients (p=0.0044).
- A significant decrease in plasma selenium levels was observed in cancer patients (p=0.005).
Conclusions:
- Histamine and selenium plasma levels are significantly reduced in lung cancer patients.
- These findings suggest histamine and selenium are involved in lung cancer pathogenesis.
- Histamine and selenium may represent potential targets for protective and therapeutic strategies against lung cancer.
